Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Roche’s Breast Cancer Strategy Paying Off, But Diversification Difficult

This article was originally published in The Pink Sheet Daily

Executive Summary

Roche’s key HER2 breast cancer franchise boasted a stellar sales performance in the first-quarter – rising 27% in the U.S. alone – and the rest of the cancer business followed suit. But, the loss of schizophrenia candidate bitopertin casts a shadow on the firm’s plans for neuroscience.

You may also be interested in...



Roche Digs In To Early Breast Cancer With New Perjeta Approvals

Better than expected FDA labeling for rising star Perjeta in neoadjuvant (before surgery) and adjuvant (after surgery) breast cancer could boost sales greatly beyond expectations, some analysts say.

Roche: Slow And Steady Wins The Race

The firm got off to a solid start in 2016, which should see its biggest launches in years, but its core strength remains executing long-term management of its key franchises.

Roche Defends HER2 Franchise After MARIANNE Failure

MARIANNE frontline breast cancer trial failure was a blow, but HER2 franchise remains strong overall, particularly with the survival results from the CLEOPATRA study and other key studies due to report, company argues.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS077090

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel